Bright Minds Biosciences & Next Generation Psychedelics

Failed to add items

Sorry, we are unable to add the item because your shopping cart is already at capacity.

Add to basket failed.

Please try again later

Add to wishlist failed.

Please try again later

Remove from wishlist failed.

Please try again later

Adding to library failed

Please try again

Follow podcast failed

Unfollow podcast failed

Bright Minds Biosciences & Next Generation Psychedelics

Listen for free

View show details

About this listen

An interview with Gideon Shapiro, Co-Founder & VP of Discovery at Bright Minds Biosciences, where we discuss recent and upcoming events in psychedelic drug development. We cover Bright Minds pipeline of 5HT2 agonists, the importance of FDA's approval of Spravato, and Compass's impending Ph2b psilocybin data, among other topics relevant in the psychedelic space.

Companies discussed during the podcast:

Bright Minds Biosciences Inc. (CSE: DRUG/OTCQB: BMBIF)
Compass Pathways plc (Nasdaq: CMPS)
Cybin Inc. (NYSE: CYBN)
Xenon Pharmaceuticals Inc. (Nasdaq: XENE)
Johnson & Johnson (NYSE: JNJ)

No reviews yet